What Mentari Therapeutics does

Mentari Therapeutics is a privately-held biotechnology company developing targeted biologic therapies for migraine prevention. The company is headquartered in Philadelphia, Pennsylvania, and is currently in pre-clinical development with no commercial products on the market. Its scientific focus is on the PACAP (pituitary adenylate cyclase-activating polypeptide) pathway, which it describes as a newly validated and biologically distinct mechanism for migraine that is separate from the established CGRP pathway targeted by currently approved migraine therapeutics.

Mentari's pipeline consists of two lead antibody programs. MT-001 is a monoclonal antibody targeting PACAP and is positioned by the company as potentially best-in-class within the anti-PACAP class. MT-002 is a bispecific antibody engineered to simultaneously block both CGRP and PACAP, intended to deliver superior efficacy compared to either monotherapy approach. Both programs are aimed at the large subpopulation of migraine patients who do not achieve adequate relief from existing anti-CGRP therapies.

The company has no disclosed revenue and operates a pre-commercial business model, relying on corporate communications and investor relations rather than product sales. In May 2026, Mentari announced a definitive all-stock merger agreement with InMed Pharmaceuticals, under which the combined entity will operate under the Mentari Therapeutics name and trade on the Nasdaq Capital Market. The transaction remains subject to regulatory approvals and closing conditions. Following regulatory approval, distribution would be expected to follow standard biopharmaceutical channels, including specialty pharmacies, hospital buying groups, and potential partnerships with larger commercial-stage pharmaceutical companies.

Name

Mentari Therapeutics

Legal name

Mentari Therapeutics

Website

https://mentaritx.com

Company type

Private

Operating status

Operating

Short description

Mentari Therapeutics is a privately-held biotechnology company developing biologic antibody therapies — MT-001 (anti-PACAP) and MT-002 (CGRP/PACAP bispecific) — for migraine prevention in patients with inadequate relief from existing anti-CGRP treatments. The company is pre-clinical and pre-revenue.

Ownership category

akta.pro rank

Product category

Neurological Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Headache & Migraine Medicine (HLAKAIAE)

Keywords

• Migraine biologics
• Anti-PACAP antibodies
• Neurological therapeutics
• Bispecific antibody therapy
• Migraine prevention drugs

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Marketing channels3 records

Core offering

Mentari Therapeutics is a pre-clinical/clinical-stage biotechnology company developing a portfolio of targeted biologic therapies for the prevention of migraine. Its pipeline comprises two lead drug candidates, MT-001 (an anti-PACAP antibody) and MT-002 (a bispecific antibody blocking both CGRP and PACAP), intended to address the unmet need among migraine patients who do not achieve adequate relief with existing anti-CGRP therapies.

Product overview

Mentari Therapeutics is developing a portfolio of targeted biologics for migraine treatment. The company has two lead programs: MT-001, a potentially best-in-class anti-PACAP antibody, and MT-002, a bispecific antibody targeting both CGRP and PACAP pathways. Both programs aim to address the unmet need in migraine care, as the majority of patients who suffer from migraines are unable to achieve adequate relief with existing anti-CGRP therapies.

Differentiator

Problem solved

Functional benefit

Brands

• MT-001: Potentially best-in-class anti-PACAP antibody for migraine treatment
• MT-002

Products and services

• MT-001 Potentially best-in-class anti-PACAP antibody for the prevention of migraine, intended for migraine patients who do not achieve adequate relief from existing anti-CGRP therapies.
• MT-002 Bispecific antibody designed to block both CGRP and PACAP pathways, with the potential to provide superior efficacy compared to either monotherapy alone in migraine prevention.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• InMed PharmaceuticalscoreStrategic or Co-development Partner · 1 May 2026InMed Pharmaceuticals and Mentari Therapeutics announced a definitive merger agreement in an all-stock transaction. Upon closing, the combined entity will operate under the name Mentari Therapeutics and trade on the Nasdaq Capital Market with a new ticker symbol. This merger is intended to advance migraine prevention therapies and remains subject to regulatory approvals and other closing conditions.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Direct peers

• Pfizer: Pfizer acquired Biohaven and now markets Nurtec ODT (rimegepant), a CGRP receptor antagonist for acute and preventive treatment of migraine. Pfizer is the leading large-pharma competitor in the migraine CGRP space and is the type of strategic acquirer that a focused migraine biologics biotech would court as a partner.
• AbbVie: AbbVie markets Qulipta (atogepant) for migraine prevention, a CGRP receptor antagonist acquired through its Allergan acquisition. AbbVie competes with Mentari's antibody-based approach through an oral small-molecule CGRP therapy targeting similar migraine patients and prescribing physicians.
• Teva Pharmaceutical: Teva markets Ajovy (fremanezumab), an anti-CGRP antibody approved for the preventive treatment of migraine. Teva competes in the same biologic migraine prevention category as Mentari's anti-PACAP and bispecific programs and shares the same prescriber and payor audiences.
• Novartis: Novartis co-commercializes Aimovig with Amgen outside the United States and is a primary global commercial partner for the leading anti-CGRP migraine antibody. Novartis's neurology footprint and migraine franchise make it a likely strategic competitor or acquirer for PACAP-targeting biologics.
• Eli Lilly: Eli Lilly commercializes Emgality (galcanezumab), an anti-CGRP antibody for migraine prevention, and has publicly disclosed PACAP-pathway antibody programs. Mentari's MT-001 (anti-PACAP) and MT-002 (CGRP/PACAP bispecific) compete directly with the same migraine biologic targets and overlap heavily in prescriber audience.
• Amgen: Amgen co-commercializes Aimovig (erenumab) with Novartis, the first-to-market anti-CGRP antibody for migraine prevention. Amgen is the established reference competitor for monoclonal antibodies targeting the migraine CGRP pathway and operates at scale that any new entrant must compete against commercially.
• Lundbeck: Lundbeck markets Vyepti (eptinezumab), an IV anti-CGRP antibody for migraine prevention acquired through its purchase of Alder Biopharmaceuticals. Vyepti is one of the four approved anti-CGRP migraine antibodies and competes for the same prescriber share that Mentari would target post-approval.

Emerging players

• Hinge Bio: Hinge Bio is an early-stage immunology and oncology antibody discovery company that, like Mentari, develops biologic antibody candidates from emerging biology platforms. It represents a comparable pre-commercial antibody-discovery biotech peer in scale and stage, though its therapeutic indications differ from migraine.
• Annexon: Annexon is a clinical-stage biotechnology company developing antibody therapeutics for neuroinflammatory and neurodegeneration disorders (e.g., Annexin A1 path). Like Mentari, Annexon is an early-stage antibody biotech focused on neurology indications, with comparable pipeline-stage profile even though its target biology is distinct.

Others

• Ionis Pharmaceuticals: Ionis is a leading antisense oligonucleotide platform company with multiple CNS and neurology programs (including migraine-adjacent neurology). While its modality is antisense rather than antibodies, it is frequently benchmarked as a comparable CNS-focused targeted biologics platform with a public listing and similar development timeline dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mentari Therapeutics